NEW YORK – HTG Molecular Diagnostics said in a regulatory document on Thursday that it may offer up to $20 million in shares of its common stock from time to time.
It also signed a sales agreement with Cantor Fitzgerald for the possible sale of the shares, the Tucson, Arizona-based molecular profiling firm said in a document filed with the US Securities and Exchange Commission.